Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Neoplasms 3Advanced Solid Tumors 2Vipoma 1Thyroid cancer, Hurthle cell 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Somatostatinoma 1Solid Tumors 1Rectal Neoplasms 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Lung Neoplasms 1Insulinoma 1Histologically or Cytologically Documented Solid Tumors 1Glucagonoma 1Gastrointestinal Stromal Tumors 1Gastrointestinal Neoplasms 1Gastrinoma 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Medullary 1Carcinoma, Islet Cell 1Breast Neoplasms 1Adenoma, Islet Cell 1Adenocarcinoma, Follicular 1

Interventions

Trastuzumab 2Octreotide 2Leucovorin 2tipifarnib 1motesanib diphosphate 1epothilone B 1batifiban 1Thalidomide 1Temozolomide 1Sorafenib 1Salts 1Oxaliplatin 1Melphalan 1Irinotecan 1Interleukin-12 Subunit p35 1Interleukin-12 1Immunoglobulin G 1Gefitinib 1Fluorouracil 1Floxuridine 1Fentanyl 1Everolimus 1Disulfides 1Capecitabine 1Bevacizumab 1Acetates 190Y-octreotide, DOTA-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Vipoma × motesanib diphosphate × Clear all
NCT00427349 2023-07-05

AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

Eastern Cooperative Oncology Group

Phase 2 Completed
46 enrolled 7 charts
EndocrineNET

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡